JPWO2020006458A5 - - Google Patents

Info

Publication number

JPWO2020006458A5

JPWO2020006458A5 JP2020572953A JP2020572953A JPWO2020006458A5 JP WO2020006458 A5 JPWO2020006458 A5 JP WO2020006458A5 JP 2020572953 A JP2020572953 A JP 2020572953A JP 2020572953 A JP2020572953 A JP 2020572953A JP WO2020006458 A5 JPWO2020006458 A5 JP WO2020006458A5

Authority

JP

Japan

Prior art keywords

muscle

promoter

weeks

raav

muscle fiber

Prior art date

2022-06-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 210000001087 myotubule Anatomy 0.000 claims description 62
• 239000000203 mixture Substances 0.000 claims description 33
• 210000003205 muscle Anatomy 0.000 claims description 15
• 102000046744 Calpain-3 Human genes 0.000 claims description 14
• 108030001375 Calpain-3 Proteins 0.000 claims description 14
• 241000702421 Dependoparvovirus Species 0.000 claims description 13
• 239000002773 nucleotide Substances 0.000 claims description 11
• 125000003729 nucleotide group Chemical group 0.000 claims description 11
• 108090000623 proteins and genes Proteins 0.000 claims description 11
• 239000000835 fiber Substances 0.000 claims description 9
• 108091033319 polynucleotide Proteins 0.000 claims description 9
• 239000002157 polynucleotide Substances 0.000 claims description 9
• 102000040430 polynucleotide Human genes 0.000 claims description 9
• 230000000694 effects Effects 0.000 claims description 8
• 230000001590 oxidative effect Effects 0.000 claims description 8
• 102000004169 proteins and genes Human genes 0.000 claims description 8
• 108010085238 Actins Proteins 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 229940079593 drug Drugs 0.000 claims description 6
• 239000003623 enhancer Substances 0.000 claims description 6
• 210000004165 myocardium Anatomy 0.000 claims description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 5
• 206010028289 Muscle atrophy Diseases 0.000 claims description 5
• 108010065729 Troponin I Proteins 0.000 claims description 5
• 210000002808 connective tissue Anatomy 0.000 claims description 5
• 238000010255 intramuscular injection Methods 0.000 claims description 5
• 238000010253 intravenous injection Methods 0.000 claims description 5
• 230000020763 muscle atrophy Effects 0.000 claims description 5
• 201000000585 muscular atrophy Diseases 0.000 claims description 5
• 210000003462 vein Anatomy 0.000 claims description 5
• 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 4
• 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 4
• 108091000080 Phosphotransferase Proteins 0.000 claims description 4
• 102000013394 Troponin I Human genes 0.000 claims description 4
• 239000003795 chemical substances by application Substances 0.000 claims description 4
• CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
• 230000002414 glycolytic effect Effects 0.000 claims description 4
• 102000020233 phosphotransferase Human genes 0.000 claims description 4
• 108091027981 Response element Proteins 0.000 claims description 3
• 239000007927 intramuscular injection Substances 0.000 claims description 3
• 102000007469 Actins Human genes 0.000 claims description 2
• 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 2
• 102100036912 Desmin Human genes 0.000 claims description 2
• 108010044052 Desmin Proteins 0.000 claims description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
• 206010021143 Hypoxia Diseases 0.000 claims description 2
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 210000005045 desmin Anatomy 0.000 claims description 2
• 230000001146 hypoxic effect Effects 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 210000000663 muscle cell Anatomy 0.000 claims description 2
• 230000002107 myocardial effect Effects 0.000 claims description 2
• 150000003431 steroids Chemical class 0.000 claims description 2
• 108090000362 Lymphotoxin-beta Proteins 0.000 claims 2
• 239000003470 adrenal cortex hormone Substances 0.000 claims 1
• RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 description 6
• 108090000565 Capsid Proteins Proteins 0.000 description 3
• 102100023321 Ceruloplasmin Human genes 0.000 description 3
• 102000004903 Troponin Human genes 0.000 description 3
• 108090001027 Troponin Proteins 0.000 description 3
• 125000003275 alpha amino acid group Chemical group 0.000 description 2
• 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1